Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) CFO Sells $26,970.84 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Ben Taylor sold 7,956 shares of the company’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $3.39, for a total transaction of $26,970.84. Following the sale, the chief financial officer owned 1,180,318 shares of the company’s stock, valued at $4,001,278.02. This represents a 0.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Recursion Pharmaceuticals Trading Down 3.6%

Shares of RXRX opened at $3.25 on Friday. The stock has a market capitalization of $1.71 billion, a P/E ratio of -2.20 and a beta of 0.97. Recursion Pharmaceuticals, Inc. has a twelve month low of $2.98 and a twelve month high of $7.18. The company has a quick ratio of 5.50, a current ratio of 5.50 and a debt-to-equity ratio of 0.01. The firm has a fifty day simple moving average of $3.90 and a two-hundred day simple moving average of $4.53.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Wednesday, February 25th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.07. The firm had revenue of $35.54 million for the quarter, compared to analysts’ expectations of $24.56 million. Recursion Pharmaceuticals had a negative net margin of 863.37% and a negative return on equity of 63.98%. The company’s revenue for the quarter was up 671.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.53) earnings per share. On average, research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Analyst Ratings Changes

RXRX has been the subject of a number of recent analyst reports. Morgan Stanley set a $11.00 price target on Recursion Pharmaceuticals in a research report on Wednesday, December 17th. JPMorgan Chase & Co. upgraded Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $10.00 to $11.00 in a research report on Wednesday, December 17th. UBS Group set a $11.00 target price on Recursion Pharmaceuticals in a research note on Wednesday, December 17th. Needham & Company LLC restated a “buy” rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Thursday, February 26th. Finally, Wall Street Zen raised Recursion Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Saturday, February 28th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $9.40.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. TD Waterhouse Canada Inc. lifted its stake in shares of Recursion Pharmaceuticals by 64.1% in the 2nd quarter. TD Waterhouse Canada Inc. now owns 5,631 shares of the company’s stock valued at $29,000 after purchasing an additional 2,200 shares during the period. Xponance Inc. boosted its position in shares of Recursion Pharmaceuticals by 8.0% during the third quarter. Xponance Inc. now owns 30,020 shares of the company’s stock valued at $146,000 after purchasing an additional 2,221 shares in the last quarter. Main Management ETF Advisors LLC grew its stake in Recursion Pharmaceuticals by 1.7% in the second quarter. Main Management ETF Advisors LLC now owns 142,914 shares of the company’s stock worth $723,000 after purchasing an additional 2,328 shares during the period. NewEdge Advisors LLC raised its holdings in Recursion Pharmaceuticals by 28.1% in the second quarter. NewEdge Advisors LLC now owns 11,061 shares of the company’s stock worth $56,000 after purchasing an additional 2,428 shares in the last quarter. Finally, Equitable Holdings Inc. raised its holdings in Recursion Pharmaceuticals by 7.1% in the third quarter. Equitable Holdings Inc. now owns 39,400 shares of the company’s stock worth $192,000 after purchasing an additional 2,600 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.